| Literature DB >> 33066266 |
Monica Currò1, Giuseppa Visalli1, Giovanni Francesco Pellicanò2, Nadia Ferlazzo1, Maria Giovanna Costanzo1, Flavia D'Andrea3, Daniela Caccamo1, Giuseppe Nunnari3, Riccardo Ientile1.
Abstract
Conflicting results on the involvement of vitamin D deficiency in inflammatory and immune response in HIV+ subjects are reported. We aimed to characterize the possible influence of vitamin D status on changes in expression of tissue transglutaminase gene (TGM2) and other genes involved in inflammatory response and autophagy in peripheral blood mononuclear cells (PBMC) from HIV+ subjects. HIV+ subjects (n = 57) under antiretroviral therapy (ART) and healthy controls (n = 40) were enrolled. mRNA levels of 1-alpha-hydroxylase (CYP27B1), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), TGM2, microtubule-associated protein 1A/1B-light chain 3 (LC3), autophagy-related 5 homolog (ATG5), and Beclin 1 (BECN1) were quantified by real-time PCR. In HIV+ subjects, 25(OH)D3 plasma levels were negatively correlated with time since HIV diagnosis. In PBMC from HIV+ subjects, increases in gene expression of TNF-α and IFN-γ in comparison to controls were observed. The highest increase in TNF-α transcripts was observed in HIV+ subjects with deficient 25(OH)D3 levels. Autophagy-related genes LC3, ATG5, and BECN1 were down-regulated in HIV+ subjects. Moreover, TGM2 transcripts were up-regulated in PBMC from HIV+ subjects with 25(OH)D3 deficiency. Changes observed in PBMC from HIV+ subjects appeared to be dependent on vitamin D status. The present results suggest that vitamin D deficiency is associated with changes in the expression of markers of inflammation and autophagy, resulting in immune cell dysfunction.Entities:
Keywords: HIV; autophagy; cytokines; inflammation; peripheral blood mononuclear cells; tissue transglutaminase; vitamin D
Mesh:
Substances:
Year: 2020 PMID: 33066266 PMCID: PMC7588966 DOI: 10.3390/ijms21207558
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Main clinical characteristics of the 57 HIV+ subjects included in the cohort.
| Characteristic | Mean ± SEM |
|---|---|
| Age | 43.2 ± 1.8 |
| Sex (female/male) | 23/34 |
| Time since HIV diagnosis (months) | 93.1 ± 10.1 |
| HIV viral load (copies/mL) | 41.3 ± 26.4 |
SEM: standard error of the mean.
Figure 1Correlation analysis between 25(OH)D3 plasma levels and time since HIV diagnosis.
Figure 2CYP27B1 expression in peripheral blood mononuclear cells (PBMC) from HIV+ and healthy subjects. mRNA transcript levels were evaluated by real-time PCR. The results are expressed as mean ± SEM. * p < 0.05 significant difference in comparison to healthy subjects with sufficient 25(OH)D3 levels.
Figure 3Gene expression of both tumor necrosis factor-α (TNF-α) (A) and interferon-γ (IFN-γ) (B) in PBMC from HIV+ and healthy subjects. mRNA transcript levels were evaluated by real-time PCR. The results are expressed as mean ± SEM. *** p < 0.001 significant differences in comparison to healthy subjects with sufficient 25(OH)D3 levels; & p < 0.05 and && p < 0.01 significant differences in comparison to healthy subjects with insufficient 25(OH)D3 levels; # p < 0.05 significant differences in comparison to healthy subjects with deficient 25(OH)D3 levels; § p < 0.05 significant difference in comparison to HIV+ subjects with sufficient 25(OH)D3 levels.
Figure 4Gene expression of microtubule-associated protein 1A/1B-light chain 3 (LC3) (A), autophagy-related 5 homolog (ATG5) (B), and Beclin 1 (BECN1) (C) in PBMC from HIV+ and healthy subjects. mRNA transcript levels were evaluated by real-time PCR. The results are expressed as mean ± SEM. & p < 0.05 and &&& p < 0.001 significant differences in comparison to healthy subjects with insufficient 25(OH)D3 levels; # p < 0.05, ## p < 0.01, and ### p < 0.001 significant differences in comparison to healthy subjects with deficient 25(OH)D3 levels; § p < 0.05 significant difference in comparison to HIV+ subjects with sufficient 25(OH)D3 levels.
Figure 5Tissue transglutaminase (TG2) expression in PBMC from HIV+ and healthy subjects. (A) mRNA transcript levels were evaluated by real-time PCR. The results are expressed as mean ± SEM. (B) Western blot analysis of TG2. (C) Densitometric analysis of immunoblots. The results are representative of the values (mean ± SEM) obtained from eight subjects for each group. * p < 0.05 significant difference in comparison to healthy subjects with sufficient 25(OH)D3 levels; $ p < 0.05 significant difference in comparison to HIV+ subjects with sufficient 25(OH)D3 levels; & p < 0.05 significant difference in comparison to HIV+ subjects with insufficient 25(OH)D3 levels.
Generalized linear model (GLM) for gene expression, accounting for the influence of HIV infection, 25(OH)D3 levels, gender, age, and time since HIV diagnosis.
|
|
|
|
|
| HIV infection | −0.301 | −0.4932; −0.110 |
|
| Gender | 0.116 | −0.022; 0.254 | 0.098 |
| Age | 0.001 | −0.007; 0.006 | 0.899 |
| 25(OH)D3 levels | 0.002 | 0.000; 0.005 | 0.072 |
| Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.283 |
|
| |||
| HIV infection | 0.622 | 0.403; 0.842 |
|
| Gender | 0.075 | −0.084; 0.233 | 0.355 |
| Age | 0.004 | −0.003; 0.011 | 0.279 |
| 25(OH)D3 levels | −0.003 | −0.006; −0.001 |
|
| Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.546 |
|
| |||
| HIV infection | 0.606 | 0.313; 0.900 |
|
| Gender | 0.040 | −0.171; 0.252 | 0.709 |
| Age | −0.006 | −0.016; 0.003 | 0.210 |
| 25(OH)D3 levels | −0.005 | −0.008; −0.001 |
|
| Time since HIV diagnosis # | −0.002 | −0.005; 0.002 | 0.983 |
|
| |||
| HIV infection | −0.280 | −0.499; −0.060 |
|
| Gender | −0.024 | −0.182; 0.134 | 0.763 |
| Age | 0.001 | −0.006; 0.008 | 0.745 |
| 25(OH)D3 levels | 0.002 | −0.001; 0.005 | 0.176 |
| Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.477 |
|
| |||
| HIV infection | −0.334 | −0.525; −0.143 |
|
| Gender | 0.086 | −0.051; 0.224 | 0.218 |
| Age | 0.005 | −0.001; 0.011 | 0.105 |
| 25(OH)D3 levels | 0.003 | 0.001; 0.005 |
|
| Time since HIV diagnosis # | −0.001 | −0.003; 0.001 | 0.729 |
|
| |||
| HIV infection | −0.168 | −0.451; 0.0115 | 0.245 |
| Gender | −0.092 | −0.296; 0.113 | 0.379 |
| Age | 0.006 | −0.003; 0.016 | 0.178 |
| 25(OH)D3 levels | 0.002 | −0.001; 0.006 | 0.263 |
| Time since HIV diagnosis # | −0.001 | −0.002; 0.002 | 0.874 |
|
| |||
| HIV infection | 0.025 | −0.158; 0.209 | 0.787 |
| Gender | −0.007 | −0.139; 0.125 | 0.916 |
| Age | 0.002 | −0.004; 0.008 | 0.490 |
| 25(OH)D3 levels | −0.003 | −0.006; −0.001 |
|
| Time since HIV diagnosis # | −0.002 | −0.003; 0.001 | 0.925 |
Bold font for p-values indicates statistically significant differences at a level ≤ 0.05. # This variable has only been tested on HIV+ subjects.
Primer sequences used for SYBR green real-time PCR.
| Gene | Primer | Sequence 5′→ 3′ |
|---|---|---|
|
| forward | TGGTTACAGGAAGTCCCTTGCC |
|
| reverse | ATGCTATCACCTCCCCTGTGTG |
|
| forward | GGAACCCTGAACAACGTAGTC |
|
| reverse | AGTCCGAACTTGTAAAATTCCCC |
|
| forward | CCTTACGGAGTCCAACCTCA |
|
| reverse | CCGTCTTCTGCTCCTCAGTC |
|
| forward | GTGAGGAGGACGAACATC |
|
| reverse | GAGCCAGAAGAGGTTGAG |
|
| forward | GCAGCCAACCTAAGCAAGAT |
|
| reverse | TCACCTGACACATTCAAGTTCTG |
|
| forward | CGGTGATAATAGAACGATACAAG |
|
| reverse | CTGAGATTGGTGTGGAGAC |
|
| forward | TGCCTGAACAGAATCATCCTT |
|
| reverse | CCAGCCCAGTTGCCTTAT |
|
| forward | ACAGTGAACAGTTACAGATGGA |
|
| reverse | CTCAGCCTGGACCTTCTC |
Abbreviations: β-ACT, β-actin; CYP27B1, 1α-hydroxylase; TGM2, tissue transglutaminase; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; LC3, microtubule-associated protein 1A/1B-light chain 3; ATG5, autophagy-related 5; BECN1, Beclin 1.